Lymphoproliferative disorder involving the cervix in a patient being treated with FK-506.
FK-506 is an immunosuppressive agent used mainly to prevent allograft rejection in organ transplant patients. Recently, it has been applied as a treatment for patients with autoimmune disorders. An entity called posttransplant lymphoproliferative disorder (PTLD) is a well-recognized result of immunosuppression in transplant patients receiving long-term immunosuppression. This disorder is a complication of treatment with FK-506 in 0.7 to 1.6% of transplant patients and is usually of B-cell origin. A majority of patients have serologic evidence of EBV infection. We report a case of a patient receiving long-term FK-506 therapy for multiple sclerosis who developed lymphoproliferative disorder involving the cervix. We will discuss the possible role of FK-506 initiation of this tumor.
Sunyecz
J A
JA
Department of Obstetrics, Gynecology, and Reproductive Sciences and Pathology, Magee-Womens Hospital, University of Pittsburgh, Pennsylvania 15213, USA.
Price
F V
FV
Trucco
G
G
Thomas
R
R
Swerdlow
S H
SH
D000328:Adult; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D008232:Lymphoproliferative Disorders / Q000139:chemically induced* / Q000601:surgery; D009103:Multiple Sclerosis / Q000188:drug therapy; D016559:Tacrolimus / Q000009:adverse effects*; D002577:Uterine Cervical Diseases / Q000139:chemically induced* / Q000601:surgery
D007166:Immunosuppressive Agents; D016559:Tacrolimus